team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Kesimpta (ofatumumab) may now be prescribed through the National Health Service (NHS) of England and Wales as an at-home, self-administered treatment for people with relapsing-remitting multiple sclerosis (RRMS) who are either having relapses or have other evidence of MS activity. A poster presentation at the AAN meeting, based on Phase 3 data in newly diagnosed patients, also showed it effective at preventing disability progression in the absence of a relapse in this group. The National Institute for Health Care and Excellence (NICE) made the recommendation to include Kesimpta in the NHS, allowing RRMS patients to access it at low and fixed prices, following Kesimpta’s recent approval in the U.K. for relapsing forms of multiple sclerosis (MS).